Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Immunicum AB (publ) Interim Report January - March 2019 | |||||||||||||||||||||||||||||||||||
By: Nasdaq / GlobeNewswire - 25 Apr 2019 | Back to overview list |
||||||||||||||||||||||||||||||||||
Press Release 25 April 2019 Immunicum AB (publ) Interim Report January - March 2019 Preparations for Upcoming Clinical Data in the MERECA and GIST Studies and First Patient Treated in the ILIAD Study Significant Events During January - March
Significant Events After End of Period
Financial Summary
CEO Comment - First Quarter Immunicum has completed a productive first quarter of 2019 with the inclusion of the first patient in the Phase Ib/II multi-indication checkpoint inhibitor combination study, ILIAD, and the publication of the final data analysis from the Phase I/II clinical trial in hepatocellular carcinoma in Frontiers in Oncology. Backed by the recent financing round, the Company is preparing for important near-term milestones aimed at providing additional validation of the potential of our lead candidate, ilixadencel. Throughout the rest of the year, our central focus will remain on the upcoming data announcements from our clinical trials which include the global Phase II MERECA study in metastatic renal cell carcinoma and the Phase I/ II study in gastrointestinal stromal tumors (GIST). We also aim to provide an update from the recently initiated Phase Ib/II ILIAD study in head and neck cancer, non-small cell lung cancer and gastric and gastroesophageal junction adenocarcinoma. MERECA will for the first time provide data on ilixadencel in combination with Sutent® (sunitinib) versus Sutent® (sunitinib) alone. The study was designed to provide information on patient survival, safety, tumor-specific immune activation and potential clinical efficacy in kidney cancer patients. These results will be important to guide the further development of ilixadencel regardless of indication. The Phase Ib/II ILIAD trial complements MERECA as it will test ilixadencel in a variety of indications as well as in combination with checkpoint inhibitors. It is important to note that the two trials are not dependent on each other; they represent our strategy to build a broad database supportive of ilixadencel becoming a backbone component of a range of cancer therapy regimens. Apart from our focus on the upcoming results, our corporate goals for the remainder of the year include continuing to share Immunicum's story, scientific approach and progress with the international pharmaceutical industry as well as the scientific and financial communities. We will continue to pursue opportunities to present at scientific conferences in addition to publishing in medical journals where our data have been reviewed by leading, independent experts in the field. Immunicum is off to a great start this year and has many exciting developments to come. With each data readout, we will gain more insights that will help steer the Company and enable us to effectively reach our corporate and clinical goals with the overarching vision of contributing to the fight against cancer. Carlos de Sousa CEO The full quarterly report is available on: http://immunicum.se/investors/financial-reports/ The information contained in this report is that which Immunicum (publ), is obliged to publish in accordance with the Swedish Securities Market Act (SFS 2007:528). The information was submitted for publication, through the agency of the contact persons set out below, on April 25, 2019, at 8:00 CET. For more information, please contact: Carlos de Sousa, CEO, Immunicum Michaela Gertz, CFO, Immunicum Media Relations Gretchen Schweitzer and Joanne Tudorica
Attachment |
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |